UBS Group
SGMO

UBS Group’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

UBS Group’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,000
Closed -$9K – 8099
2015
Q4 		$9K Hold
1,000
– – ﹤0.01% 7366
2015
Q3 		$6K Hold
1,000
– – ﹤0.01% 7613
2015
Q2 		$11K Hold
1,000
– – ﹤0.01% 7401
2015
Q1 		$16K Sell
1,000
-39,400
-98% -$610K ﹤0.01% 7220
2014
Q4 		$614K Buy
+40,400
New +$491K ﹤0.01% 4010

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

UBS Group's SGMO Position: Q1 2026 in Review

UBS Group increased its SANGAMO THERAPEUTICS INC (SGMO) stake by 151% in Q1 2026, buying an estimated $615K and bringing the position to 2,570,992 shares worth $635K. The position accounts for ﹤0.01% of the portfolio, ranked #5901.

UBS Group first reported a position in SGMO in Q4 2014 and has held it in 46 quarters since. The position peaked at $4.33M in Q1 2021. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • UBS Group held 2,570,992 shares of SANGAMO THERAPEUTICS INC worth $635K as of Q1 2026.
  • UBS Group bought 1,546,517 SANGAMO THERAPEUTICS INC shares in Q1 2026, an estimated $615K.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5901 holding.
  • UBS Group first reported a position in SANGAMO THERAPEUTICS INC in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's SANGAMO THERAPEUTICS INC position peaked at $4.33M in Q1 2021.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.